91453-04-2
Chemical Structure
Cinnamic acid-d6
Synonym(s): 3-Phenylacrylic acid-d6;β-Phenylacrylic acid-d6
- CAS No.: 91453-04-2
- Formula:C9H2D6O2
- Molecular Weight:154.20
InChIKey: WBYWAXJHAXSJNI-UMENIHJVSA-N
SMILES: OC(/C=C([2H])/C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H])=O
Biological Activity: Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cinnamic acid-d6 | 99.9% | Cinnamic acid-d6 is the deuterium labeled Cinnamic acid. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cinnamic acid (Standard) | ≥98% | Cinnamic acid (Standard) is the analytical standard of Cinnamic acid. This product is intended for research and analytical applications. Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cinnamic acid-13C3 | 99.91% | Cinnamic acid-13C3 (3-Phenylacrylic acid-13C3) is the 13C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cinnamic acid-d7 | Cinnamic acid-d7 (3-Phenylacrylic acid-d7) is the deuterium labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cinnamic acid | 99.98% | Cinnamic acid has potential use in cancer intervention, with IC50s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||